argenx SE (NASDAQ:ARGX) Receives $658.39 Average PT from Brokerages

argenx SE (NASDAQ:ARGX - Get Free Report) has been given an average rating of "Moderate Buy" by the twenty-two research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eighteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $658.39.

A number of analysts have recently issued reports on ARGX shares. Wedbush reissued an "outperform" rating and set a $655.00 target price on shares of argenx in a research note on Tuesday, December 3rd. Guggenheim boosted their target price on shares of argenx from $585.00 to $665.00 and gave the company a "buy" rating in a research note on Friday, November 1st. JMP Securities upped their price objective on shares of argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a research note on Tuesday, January 14th. Wells Fargo & Company upped their price objective on shares of argenx from $639.00 to $723.00 and gave the stock an "overweight" rating in a research note on Thursday, December 19th. Finally, Robert W. Baird lowered shares of argenx from an "outperform" rating to a "neutral" rating and upped their price objective for the stock from $515.00 to $650.00 in a research note on Friday, November 1st.

Hedge Funds Weigh In On argenx

Large investors have recently added to or reduced their stakes in the company. Stifel Financial Corp increased its holdings in shares of argenx by 15.3% during the third quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock valued at $4,788,000 after acquiring an additional 1,170 shares in the last quarter. FMR LLC increased its holdings in shares of argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company's stock valued at $2,598,445,000 after acquiring an additional 1,265,486 shares in the last quarter. Simplify Asset Management Inc. increased its holdings in shares of argenx by 64.0% during the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company's stock valued at $1,311,000 after acquiring an additional 944 shares in the last quarter. Ritholtz Wealth Management increased its holdings in shares of argenx by 85.5% during the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock valued at $552,000 after acquiring an additional 414 shares in the last quarter. Finally, Westfield Capital Management Co. LP acquired a new position in shares of argenx during the third quarter valued at about $571,000. 60.32% of the stock is currently owned by institutional investors.

argenx Trading Down 1.8 %

Shares of ARGX traded down $11.93 during trading hours on Tuesday, reaching $639.41. 266,806 shares of the company traded hands, compared to its average volume of 265,453. The firm has a market cap of $38.85 billion, a price-to-earnings ratio of -726.60 and a beta of 0.58. argenx has a 12-month low of $349.86 and a 12-month high of $678.21. The stock's fifty day moving average price is $639.59 and its 200 day moving average price is $581.81.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.